These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 23581649)
1. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. Kim GH; Levy A; Compoginis G J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649 [TBL] [Abstract][Full Text] [Related]
2. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191 [TBL] [Abstract][Full Text] [Related]
3. Vemurafenib-induced neutrophilic panniculitis. Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248 [TBL] [Abstract][Full Text] [Related]
4. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib. Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793 [TBL] [Abstract][Full Text] [Related]
5. Panniculitis in patients treated with BRAF inhibitors: a case series. Choy B; Chou S; Anforth R; Fernández-Peñas P Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511 [TBL] [Abstract][Full Text] [Related]
6. Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma. Clarke M; Ortel B; Brockstein B; Rojanapremsuk T; Victor T; Thomas A; Cibull T J Cutan Pathol; 2013 Oct; 40(10):884-6. PubMed ID: 23924408 [TBL] [Abstract][Full Text] [Related]
8. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature. Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695 [TBL] [Abstract][Full Text] [Related]
9. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570 [No Abstract] [Full Text] [Related]
10. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma. West ES; Williams VL; Morelli JG Pediatr Dermatol; 2015; 32(1):153-4. PubMed ID: 24602192 [TBL] [Abstract][Full Text] [Related]
12. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma. Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301 [TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
14. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
18. Vemurafenib: a guide to its use in unresectable or metastatic melanoma. Keating GM; Lyseng-Williamson KA Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082 [TBL] [Abstract][Full Text] [Related]